— Know what they know.
Not Investment Advice

PROK NASDAQ

ProKidney Corp.
1W: -12.9% 1M: -26.2% 3M: -26.5% YTD: -30.5% 1Y: +92.2% 3Y: -83.0%
$1.55
-0.06 (-3.73%)
Pre-Market: $1.58 (+0.03, +1.94%)
Weekly Expected Move ±5.7%
$1 $2 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 27 · $499.5M mcap · 104M float · 0.798% daily turnover · Short 69% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$499.5M
52W Range0.54-7.13
Volume876,898
Avg Volume832,000
Beta1.75
Dividend
Analyst Ratings
6 Buy 1 Hold 1 Sell
Consensus Buy
Company Info
CEOBruce Culleton
Employees204
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-30
2000 Frontis Plaza Blvd.
Winston-Salem, NC 27103
US
336 999 7028
About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Recent Insider Trades

NameTypeSharesPriceDate
Control Empresarial C-Conversion 63,118,645 2026-04-28
Control Empresarial C-Conversion 63,118,645 2026-04-28
Control Empresarial C-Conversion 63,118,645 2026-04-28
Coulston James A-Award 600,000 $2.24 2026-03-01
Weber Darin J. A-Award 400,000 $2.24 2026-03-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms